|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ann Thorac Surg 1996;61:1222
© 1996 The Society of Thoracic Surgeons
Division of Cardiac Surgery, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02215
| The first 20% of the full text of this article appears below. |
See also page 1217.
The clinical course and natural history of infective endocarditis has been radically modified by the discovery of antibodies, and by the introduction of valve replacement devices. Antibiotic treatment prevented death resulting from overwhelming and uncontrolled sepsis. Consequently congestive heart failure secondary to severe valvular dysfunction emerged as the major cause of morbidity and mortality. Correcting valvular dysfunction with valve replacement has further improved the outcome for patients with infective endocarditis. Nevertheless, in a significant number of patients with valvular prosthesis a more serious and devastating form of endocarditis emerged in the form of prosthetic valve endocarditis, irrespective of whether the initial procedure was performed for an infective or noninfective cause. As a result patients with prosthetic valves became part and parcel
Related Article
Ann. Thorac. Surg. 1996 61: 1217-1222.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |